EUVIMEDEUVIMED entdecken
ValidierungsstudieOpen Access · CC BY-NC 4.0

Development and validation of a molecular classifier of meningiomas

Alexander P Landry, Justin Z Wang, Jeff Liu, Vikas Patil, Chloe Gui, Zeel Patel, Andrew Ajisebutu, Yosef Ellenbogen, Qingxia Wei, Olivia Singh, Julio Sosa, Sheila Mansouri und 20 weitere

Neuro-Oncology · 2025

DOI: 10.1093/neuonc/noae242 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift Neuro-Oncology, 2025. Verfasst von Alexander P Landry und 31 weiteren Autor:innen. Beteiligte Einrichtung: Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Meningioma, DNA Methylation, Meningeal Neoplasms, Biomarkers, Tumor. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, Brain Tumour Charity, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Meningiomas exhibit considerable clinical and biological heterogeneity. We previously identified 4 distinct molecular groups (immunogenic, NF2-wildtype, hypermetabolic, and proliferative) that address much of this heterogeneity. Despite the utility of these groups, the stochasticity of clustering methods and the use of multi-omics data for discovery limits the potential for classifying prospective cases. We sought to address this with a dedicated classifier.

Methods

Using an international cohort of 1698 meningiomas, we constructed and rigorously validated a machine learning-based molecular classifier using only DNA methylation data as input. Original and newly predicted molecular groups were compared using DNA methylation, RNA sequencing, copy number profiles, whole-exome sequencing, and clinical outcomes.

Results

We show that group-specific outcomes in the validation cohort are nearly identical to those originally described, with median progression-free survival (PFS) of 7.4 (4.9–Inf) years in hypermetabolic tumors and 2.5 (2.3–5.3) years in proliferative tumors (not reached in the other groups). Tumors classified as NF2-wildtype had no NF2 mutations, and 51.4% had canonical mutations previously described in this group. RNA pathway analysis revealed upregulation of immune-related pathways in the immunogenic group, metabolic pathways in the hypermetabolic group, and cell cycle programs in the proliferative group. Bulk deconvolution similarly revealed the enrichment of macrophages in immunogenic tumors and neoplastic cells in hypermetabolic and proliferative tumors with similar proportions to those originally described.

Conclusions

Our DNA methylation-based classifier, which is publicly available for immediate clinical use, recapitulates the biology and outcomes of the original molecular groups as assessed using multiple metrics/platforms that were not used in its training.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MeningiomaDNA MethylationMeningeal NeoplasmsBiomarkers, TumorMachine LearningHumansFemaleMaleMiddle AgedPrognosisMutationAdultAgedFollow-Up StudiesSurvival Rate

Stichwörter der Autor:innen

DNA methylationmeningioma | molecular classification | Neuro-Oncology | outcome prediction

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Division of Neurosurgery, Department of Surgery, University of Toronto, Toronto, Ontario, Canada.
  • MacFeeters Hamilton Neuro-Oncology Program, Princess Margaret Cancer Centre, University Health Network and University of Toronto, Toronto, Ontario, Canada.
  • Temerty School of Medicine, University of Toronto, Toronto, Ontario, Canada.
  • Department of Neurosurgery, University of Oklahoma Health Sciences Center, Tulsa, Oklahoma, USA.
  • Department of Neurological Surgery, Keck School of Medicine, USC, Los Angeles, California, USA.

ORCID-Profile: Stephen Yip, Kenneth Aldape, Gelareh Zadeh

Förderung

  • NCI NIH HHS
  • Brain Tumour Charity
  • NIH HHS
  • CIHR
  • Brain Tumor Charity United Kingdom
  • the UHN Foundation, Mary Hunter Meningioma Research Fund
  • V Foundation for Cancer Research
  • the CIHR Vanier Scholarship

Zitieren

APA

Landry, A. P., Wang, J. Z., Liu, J., Patil, V., Gui, C., Patel, Z., Ajisebutu, A., Ellenbogen, Y., Wei, Q., Singh, O., Sosa, J., Mansouri, S., Wilson, C., Cohen-Gadol, A. A., Zaazoue, M. A., Tabatabai, G., Tatagiba, M., Behling, F., Barnholtz-Sloan, J. S., …, & Zadeh, G. (2025). Development and validation of a molecular classifier of meningiomas. Neuro-Oncology. https://doi.org/10.1093/neuonc/noae242

Vancouver

Landry AP, Wang JZ, Liu J, Patil V, Gui C, Patel Z, et al. Development and validation of a molecular classifier of meningiomas. Neuro-Oncology. 2025. doi:10.1093/neuonc/noae242

BibTeX
@article{Landry2025,
  author = {Landry, Alexander P and Wang, Justin Z and Liu, Jeff and Patil, Vikas and Gui, Chloe and Patel, Zeel and Ajisebutu, Andrew and Ellenbogen, Yosef and Wei, Qingxia and Singh, Olivia and Sosa, Julio and Mansouri, Sheila and Wilson, Christopher and Cohen-Gadol, Aaron A and Zaazoue, Mohamed A and Tabatabai, Ghazaleh and Tatagiba, Marcos and Behling, Felix and Barnholtz-Sloan, Jill S and Sloan, Andrew E and Chotai, Silky and Chambless, Lola B and Rebchuk, Alexander D and Makarenko, Serge and Yip, Stephen and Mansouri, Alireza and Tsang, Derek S and Aldape, Kenneth and Gao, Andrew and International Consortium on Meningiomas (ICOM), International Consortium on Meningiomas (ICOM) and Nassiri, Farshad and Zadeh, Gelareh},
  title = {Development and validation of a molecular classifier of meningiomas},
  journal = {Neuro-Oncology},
  year = {2025},
  doi = {10.1093/neuonc/noae242}
}
Kostenlos starten →